Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial
Authors:
- John McMurrayJMJohn McMurray
- Jay N CohnJCJay N Cohn
- Marvin A KonstamMKMarvin A Konstam
- Thomas NotterTNThomas Notter
- Kurt QuitzauKQKurt Quitzau
- Frank RuschitzkaFRFrank Ruschitzka
- Thomas F LüscherTLThomas F Lüscher
- 1 July 2004
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 364 (9431) , 347-354
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Relation between changes in ejection fraction over time and subsequent mortality and morbidity in Val-HeFTJACC, 2003
- Noninvasive assessment of left ventricular remodeling: Concepts, techniques, and implications for clinical trialsJournal of Cardiac Failure, 2002
- Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET A ) Receptor Blockade in Chronic Heart FailureCirculation, 2002
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- EARTH: EndothelinA Receptor Antagonist Trial in Heart FailureHeart Drug, 2001
- Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failureJACC, 2000
- Inhibition of myocardial endothelin pathway improves long-term survival in heart failureNature, 1996
- Relation of ventricular size and function to heart failure status and ventricular dysrhythmia in patients with severe left ventricular dysfunctionThe American Journal of Cardiology, 1996
- Contribution of endogenous generation of endothelin-1 to basal vascular toneThe Lancet, 1994
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988